Gebruik van een vaste dosering voor monoklonale antilichamen binnen de oncologie

Jeroen J.M.A. Hendrikx; John B.A.G. Haanen; Emile Voest; Jan H.M. Schellens; Alwin D.R. Huitema; En Jos H. Beijnen

Gebruik van een vaste dosering voor monoklonale antilichamen binnen de oncologie

Translated title of the contribution: Fixed dosing of monoclonal antibodies in oncology

Jeroen J.M.A. Hendrikx^*, John B.A.G. Haanen, Emile Voest, Jan H.M. Schellens, Alwin D.R. Huitema, En Jos H. Beijnen

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Fixed dosing of monoclonal antibodies in oncology BACKGROUND and OBJECTIVE Most monoclonal antibodies in oncology are administered using body size-based dosing schedules. This is believed to correctforvariability in both drug distribution and elimination between patients. However, the minor effects of body size on distribution and elimination of monoclonal antibodies and their usually wide therapeutic window do not support body size-based dosing.DESIGN and METHODS We summarized effects of body weight on the pharmacokinetic parameters of monoclonal antibodies in oncology and show that a fixed dose for most of these drugs is justified. RESULTS and CONCLUSION We show that fixed dosing is justified and can improve efficiency of compounding. Moreover, drug spillage can be reduced and medication errors may become less likely.

Translated title of the contribution	Fixed dosing of monoclonal antibodies in oncology
Original language	Dutch
Pages (from-to)	21-30
Number of pages	10
Journal	Pharmaceutisch Weekblad
Volume	153
Issue number	35
Publication status	Published - 31 Aug 2018

Cite this

@article{fc5288e815bf492e90a5d12c852f53e7,

title = "Gebruik van een vaste dosering voor monoklonale antilichamen binnen de oncologie",

abstract = "Fixed dosing of monoclonal antibodies in oncology BACKGROUND and OBJECTIVE Most monoclonal antibodies in oncology are administered using body size-based dosing schedules. This is believed to correctforvariability in both drug distribution and elimination between patients. However, the minor effects of body size on distribution and elimination of monoclonal antibodies and their usually wide therapeutic window do not support body size-based dosing.DESIGN and METHODS We summarized effects of body weight on the pharmacokinetic parameters of monoclonal antibodies in oncology and show that a fixed dose for most of these drugs is justified. RESULTS and CONCLUSION We show that fixed dosing is justified and can improve efficiency of compounding. Moreover, drug spillage can be reduced and medication errors may become less likely.",

author = "Hendrikx, {Jeroen J.M.A.} and Haanen, {John B.A.G.} and Emile Voest and Schellens, {Jan H.M.} and Huitema, {Alwin D.R.} and Beijnen, {En Jos H.}",

year = "2018",

month = aug,

day = "31",

language = "Dutch",

volume = "153",

pages = "21--30",

journal = "Pharmaceutisch Weekblad",

issn = "0031-6911",

publisher = "Kon. Ned. Mij. ter Bevordering der Pharmacie (KNMP)",

number = "35",

}

TY - JOUR

T1 - Gebruik van een vaste dosering voor monoklonale antilichamen binnen de oncologie

AU - Hendrikx, Jeroen J.M.A.

AU - Haanen, John B.A.G.

AU - Voest, Emile

AU - Schellens, Jan H.M.

AU - Huitema, Alwin D.R.

AU - Beijnen, En Jos H.

PY - 2018/8/31

Y1 - 2018/8/31

N2 - Fixed dosing of monoclonal antibodies in oncology BACKGROUND and OBJECTIVE Most monoclonal antibodies in oncology are administered using body size-based dosing schedules. This is believed to correctforvariability in both drug distribution and elimination between patients. However, the minor effects of body size on distribution and elimination of monoclonal antibodies and their usually wide therapeutic window do not support body size-based dosing.DESIGN and METHODS We summarized effects of body weight on the pharmacokinetic parameters of monoclonal antibodies in oncology and show that a fixed dose for most of these drugs is justified. RESULTS and CONCLUSION We show that fixed dosing is justified and can improve efficiency of compounding. Moreover, drug spillage can be reduced and medication errors may become less likely.

AB - Fixed dosing of monoclonal antibodies in oncology BACKGROUND and OBJECTIVE Most monoclonal antibodies in oncology are administered using body size-based dosing schedules. This is believed to correctforvariability in both drug distribution and elimination between patients. However, the minor effects of body size on distribution and elimination of monoclonal antibodies and their usually wide therapeutic window do not support body size-based dosing.DESIGN and METHODS We summarized effects of body weight on the pharmacokinetic parameters of monoclonal antibodies in oncology and show that a fixed dose for most of these drugs is justified. RESULTS and CONCLUSION We show that fixed dosing is justified and can improve efficiency of compounding. Moreover, drug spillage can be reduced and medication errors may become less likely.

UR - http://www.scopus.com/inward/record.url?scp=85053659140&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85053659140

SN - 0031-6911

VL - 153

SP - 21

EP - 30

JO - Pharmaceutisch Weekblad

JF - Pharmaceutisch Weekblad

IS - 35

ER -

Gebruik van een vaste dosering voor monoklonale antilichamen binnen de oncologie

Abstract

Other files and links

Fingerprint

Cite this